Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AML
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AML
(NASDAQ:GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China.
“Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that Apollomics support for uproleselan reflects a broad level of interest in our drug candidate’s potential to make a real difference for AML patients. Clearly, for patients with relapsed/refractory disease, there is a huge unmet need,” noted Rachel King, GlycoMimetics Chief Executive Officer. “We believe that Apollomics’ track record and leadership are particularly qualified to take this program through clinical development and on to commercialization.”
The Phase 1 clinical trial in China is a part of the Phase 1 and Phase 3 bridging clinical study of APL-106 in combination with chemotherapy in adults with relapsed or refractory AML. Its principal investigator is Professor Jianxiang Wang of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The primary objective of the Phase 1 trial is to study the pharmacokinetic (PK) characteristics of APL-106 in Chinese subjects with relapsed or refractory AML and to evaluate the safety and tolerability of APL-106 in combination with chemotherapy.
(NASDAQ:GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China.
(納斯達克:甘露糖)今天宣佈,Apollology已經在APL-106(烏普羅司蘭注射液)的一期臨牀試驗中為中國首例患者提供了治療成人復發或難治性急性髓系白血病(AML)的藥物。今年2月,阿波羅經濟學在大中華區啟動了兩個第一階段研究地點。
“Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that Apollomics support for uproleselan reflects a broad level of interest in our drug candidate’s potential to make a real difference for AML patients. Clearly, for patients with relapsed/refractory disease, there is a huge unmet need,” noted Rachel King, GlycoMimetics Chief Executive Officer. “We believe that Apollomics’ track record and leadership are particularly qualified to take this program through clinical development and on to commercialization.”
他説:“在大中華區為首位患者配藥是Apollology的一項重大成就。同樣重要的是,阿波利經濟學對烏普羅塞蘭的支持反映了人們對我們的候選藥物為急性髓細胞白血病患者帶來真正改變的潛力的廣泛興趣。顯然,對於復發/難治性疾病的患者來説,有一個巨大的未得到滿足的需求,“GlycoMimtics首席執行官雷切爾·金指出。我們相信,阿波羅經濟學公司的業績記錄和領導力特別有資格帶領這一計劃完成臨牀開發並走向商業化。“
The Phase 1 clinical trial in China is a part of the Phase 1 and Phase 3 bridging clinical study of APL-106 in combination with chemotherapy in adults with relapsed or refractory AML. Its principal investigator is Professor Jianxiang Wang of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The primary objective of the Phase 1 trial is to study the pharmacokinetic (PK) characteristics of APL-106 in Chinese subjects with relapsed or refractory AML and to evaluate the safety and tolerability of APL-106 in combination with chemotherapy.
在中國進行的1期臨牀試驗是APL-106聯合化療治療成人複發性或難治性急性髓細胞白血病(AML)的1期和3期橋樑臨牀研究的一部分。它的主要研究員是中國醫學科學院血液與血液病研究所和北京協和醫學院的王建祥教授。第一階段試驗的主要目標是研究APL-106在中國復發或難治性AML患者中的藥代動力學(PK)特徵,並評估APL-106與化療聯合使用的安全性和耐受性。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧